Twitter LinkedIn
    Friday, February 3
    Login
    0 Shopping Cart
    Twitter LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Investments»Novo Holdings co-leads oversubscribed CHF100m Series C in Numab Therapeutics
    Investments

    Novo Holdings co-leads oversubscribed CHF100m Series C in Numab Therapeutics

    May 20, 20212 Mins Read
    LinkedIn Facebook Twitter Email WhatsApp
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    Novo Holdings has co-led an oversubscribed CHF100 million (approximately USD110 million) Series C financing in Numab Therapeutics AG (Numab) alongside HBM Partners, with participation from new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners, RTW Investments, fund and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.

    Numab is a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation. Nanna Lüneborg, Partner at Novo Ventures, will join Numab’s Board of Directors.

    Based near Zurich in Switzerland, Numab is creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies in the field of cancer immunotherapy and inflammation. Utilising its proprietary MATCHTM technology platform, Numab is developing a pipeline of bispecifics to simultaneously target clinically validated pathways. The financing will support the acceleration and expansion of the clinical development of Numab’s lead program, NM21-1480, into multiple cancer indications, and the advancement of the company’s pipeline of multi-specific antibodies in oncology and inflammation, into clinical trials. NM21-1480 combines binding to 4-1BB, PD-L1 and human serum albumin, thereby balancing potent anti-tumour immune activation with a desirable safety profile.

    Nanna Lüneborg, Partner, Novo Ventures and Board Director of Numab Therapeutics, says: “We are delighted to be co-leading Numab’s Series C financing together with our colleagues at HBM Partners. It is fantastic to see a major European led round attracting a broad and experienced syndicate of international investors, and a testament to the outstanding innovation in antibody platforms in Europe. We believe bispecifics as a class offer huge potential, and Numab is an exciting company with compelling technology and a highly experienced management team. The company is at a pivotal stage of its growth and this funding will enable Numab to generate significant clinical data points. It represents another example of Novo Holdings’ investment strategy to support companies built on differentiated science in areas of major unmet medical need.”

    Read more/Source: Private Equity Wire

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    Capital Investments PE Insider Private Equity
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    Euroclear moves into $9.8 trillion private asset market with Goji buy

    December 21, 2022

    CAI raises over $1B for inaugural fund and co-investment programme

    November 18, 2022

    KKR looking to sell Canadian gas producer Westbrick for $1.13B

    November 18, 2022

    Carlyle targeting $1.6B for second renewables fund

    November 18, 2022

    Comments are closed.

    Other Articles

    KKR Closes US$15 Billion Asian Fund IV

    April 6, 2021

    Foley-backed SPAC nears $7.3 billion deal with Blackstone’s Alight: sources

    January 25, 2021

    Ecovadis raises $500m in funding round led by General Atlantic and Astorg

    November 8, 2022

    Deliveroo to Raise $1.4 Billion in IPO After Lockdown Surge

    March 16, 2021

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    Twitter LinkedIn
    © 2023 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.


    Lost password?